Comment by Feb. 17 for your feedback to be reviewed by the guideline development workgroup.

The global atopic dermatitis treatment market is on the cusp of remarkable expansion, with projections indicating a surge in ...

AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

As temperatures drop, many people experience dry, red, and itchy skin, a condition that often worsens in winter.

Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of ...

Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic dermatitis, according to a study.Ruxolitinib ...

The Organising Committee is delighted to announce the seventh edition of the EAACI-ESCD Skin Allergy Meeting (SAM), Europe’s leading event dedicated to skin allergies. This year, SAM 2025 will take ...

The celebrity dermatologist talks about finding her moment of clarity in finding relief for her eczema symptoms and how she ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Long-term lebrikizumab was effective for atopic dermatitis treatment in patients who did not have adequate response to short-term treatment.

Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.